Phase 1 study of CBE-101

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

20 Jul 2024 According to a Cell BioEngines media release, Cell BioEngines, Inc., unlocked $1.75 million additional funds from SOSV and the partnership fund through the new therapeutics seed track, available for therapeutics start-ups. In addition, Cell BioEngines raised $0.25 million from Empire State Developments NY Ventures, the states venture capital arm through the Pre-Seed and seed matching fund program, the fund will support this trial
03 Jan 2024 New trial record
29 Dec 2023 According to a Cell BioEngines media release, Under the terms of the agreement, Miltenyi will begin development leading towards Good Manufacturing Practices (GMP) manufacturing of the Phase 1 clinical trial batches of Cell BioEngines CBE-101 clinical program.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com